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Background: The prognostic potential of PD-L1 is currently unclear in gastric carcinomas, although the immune
checkpoint PD-1/PD-L1 inhibitors have produced promising results in clinical trials.
Methods: We explored the prognostic implications of programmed death ligand 1 (PD-L1) in 514 consecutive
surgically-resected gastric carcinomas. Overall survival and recurrence-free survival were evaluated. Immunohistochemistry
for PD-L1, CD8, FOXP3, and PD-1, and molecular grouping by in situ hybridization for Epstein-Barr virus (EBV)-encoded
small RNAs and multiplex PCR for microsatellite instability (MSI) markers were performed. Additionally, to explore the
function inherent to PD-L1, PD-L1-specific siRNA transfection, cell proliferation, invasion, migration and apoptosis assays
were conducted in five gastric carcinoma cell lines.
Results: PD-L1(+) tumor and immune cells were observed in 101 (20%) and 244 patients (47%), respectively. “Tumoral
PD-L1(+)/immune cell PD-L1(-)/CD8+/low tumor-infiltrating lymphocytes (TILs),” and more advanced-stage tumors were
associated with unfavorable clinical outcomes in the entire cohort through multivariate analysis. Furthermore, tumoral PD-
L1(+)/FOXP3+/low TILs were associated with worse clinical outcomes in EBV-positive and MSI-high carcinomas. Tumoral
PD-L1(+) alone was an adverse prognostic factor in EBV-positive carcinomas, but not in MSI-high carcinomas, whereas
PD-L1(+) immune cells or FOXP3+/high TILs alone were correlated with a favorable prognosis. PD-L1 knockdown in gastric
carcinoma cells suppressed cell proliferation, invasion and migration, and increased apoptosis, which were all statistically
significant in two EBV(+) cell lines, but not all in three EBV(−) cell lines.
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Conclusions: The prognostic impact of PD-L1 may depend on the tumor microenvironment, and statuses of EBV and
MSI, although PD-L1 innately promotes cancer cell survival in cell-based assays. The combination of “tumoral PD-L1/
immune cell PD-L1/CD8+ TILs” may serve as an independent prognostic factor. Tumoral PD-L1(+)/immune cell PD-L1(−)/
CD8+/low TILs showing a worse prognosis may be beneficial for combinatorial therapies of anti-PD-L1/PD-1 and anti-
cytotoxic T-lymphocyte associated antigen 4 (CTLA4) that would promote effector T cells, thus attack the tumor.
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Gastric carcinoma is the third most common cancer,
and the third or fourth most common cause of cancer-
related deaths worldwide [1]. Recently, targeting pro-
grammed cell death 1 (PD-1)/programmed cell death lig-
and 1 (PD-L1) immune checkpoint inhibitors have led to
major progress in cancer immunotherapy; resulting in
positive outcomes in clinical trials across various solid
malignancies, including gastric carcinomas [2, 3]. Tumor
cells aberrantly express PD-L1, and exploit PD-1/PD-L1
molecular brakes to evade immune surveillance [4, 5].
Binding of the transmembrane PD-1 protein to its lig-
and, PD-L1, results in PD-1/T cell reoceptor inhibitory
micro-clusters, which suppress the activation of T cells
that could otherwise attack tumor cells [4].
The tumor microenvironment contains tumor cells
that evade immunity by reprogramming immune cells,
resulting in a dynamic immune environment [6]. Tumor-
infiltrating lymphocytes (TILs), particularly, CD8+ cyto-
toxic T cells, support tumor cell killing functions [7, 8].
However, their prolonged exposure to cancer cells may
lead to the loss of their effector function [8]. Furthermore,
PD-L1 promotes the initiation, maintenance, and expan-
sion of forkhead box P3 (FOXP3)+ regulatory T cells
(Treg), which inhibit antitumor CD8+ cytotoxic T cell
functions [9]. Thus, immunomodulatory TILs may play an
important role in the action of immune checkpoint block-
ades [10].
Many studies have investigated the prognostic poten-
tial of PD-L1 expression, but their data are controversial
[11]; poor [12–15], good [16], and neutral [17] prognos-
tic outcomes have all been reported. Given the convo-
luted immune interactions that occur in the tumor
microenvironment, a combinatorial analysis of PD-L1,
TILs, Epstein-Barr virus (EBV)-infection, and microsatel-
lite instability (MSI) status is required. However, very
few studies have employed such an integrative analysis.
In this study, we investigated PD-L1 expression in
tumor and stromal immune cells, TILs (CD8+, FOXP3+,
and PD-1+ cells), and their concomitant prognostic value
in a large cohort of gastric carcinomas and in molecular
groups stratified by EBV-infection and MSI status. We
aimed to define the prognostic implications of PD-L1
and immunomodulatory TILs, and further, provideguidance regarding the selection of patients for whom PD-
1/PD-L1 blockade immunotherapy could be advantageous.
Methods
Patients
We collected 514 surgically resected gastric carcinomas
at the Seoul National University Boramae Hospital
(Seoul, Korea) between 2006 and 2011. After surgical re-
section, patients in tumor stage II received adjuvant
chemotherapy with 5-fluorouracil (5-FU) or 5-FU/mito-
mycin-C, and patients in stage III or IVA, with 5-FU/cis-
platin. None of patients were treated with neoadjuvant
chemotherapy or immunotherapy. We reviewed medical
records, patient outcomes, and histopathological find-
ings, such as the World Health Organization (WHO)
histologic classification, Lauren histologic type [18], and
the tumor stage (pathological tumor-node-metastasis
(pTNM)) based on the 7th American Joint Committee
on Cancer [19]. Overall survival or recurrence-free sur-
vival was estimated from the date of surgery to death,
tumor recurrence, or the last follow-up visit. The me-
dian follow-up period for overall survival was 77 months
(mean: 63.8, range: ~ 1–128).
Generating tissue microarray blocks
After a histological review of all tumor sections, the por-
tion of deepest tumor invasion was chosen from each
donor block, and two tissue cores (diameter: 2 mm/core)
per tumor were punched out using a trephine. The tis-
sue cores were then inserted in a new recipient block
containing fifty-nine tissue cores and one ink core as a
direction marker. A total of eighteen tissue microarray
blocks were thus prepared for immunohistochemistry.
Immunohistochemistry for PD-L1, CD8, FOXP3, and PD-1
Immunohistochemistry was performed using an auto-
mated immunostainer, the BenchMark Ultra IHC/ISH
system (Ventana Medical Systems, Tucson, AZ, USA),
according to the manufacturer’s protocol. For PD-L1 im-
munohistochemistry, two different antibodies were uti-
lized: clone E1L3N® (1:30, Cell Signaling Technology,
Danvers, MA, USA) was used for tumoral PD-L1 evalu-
ation, and SP263 (Ready to use, Ventana Medical Sys-
tems) was used for stromal immune cell PD-L1
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cause they have been shown to have different efficiencies
for the detection of tumoral PD-L1 and stromal immune
cell PD-Ll [20]. We additionally conducted immunohis-
tochemistry for CD8 (Ready to use; Novocastra, Leica
Microsystems, Wetzlar, Germany), FOXP3 (236A/E7, 1:
30; Abcam, Cambridge, MA, USA), and PD-1 (NAT105,
1:30; Cell Marque, Rocklin, CA, USA).
PD-L1 expression in tumor cells was primarily scored
based on staining intensity and percentage of stained
tumor cells; any membranous staining was regarded as
“positive expression” [21]. Stromal immune cell PD-L1
was categorized as positively expressed when membran-
ous staining was present in ≥5% of the stromal immune
cells at any staining intensity [22]. The number of CD8-,
FOXP3-, or PD-1-positive cells were counted in ten con-
tiguous high-power fields in heavily infiltrated areas; the
absolute number of immunostained cells in each group
was determined as an average per high-power field
(400× magnification, 0.24 mm2) (Olympus BX51 micro-
scope; Olympus, Tokyo, Japan). Finally, groups were
classified into “low” and “high” populations based on the
median number of CD8+, FOXP3+, and PD-1+ TILs
cells, and then denoted as +/low or +/high [23].In situ hybridization for EBV-encoded small RNAs
In situ hybridization for EBV-encoded small RNAs
(EBER) was conducted using the BenchMark Ultra IHC/
ISH system and the INFORM EBER probe (Ventana
Medical Systems) according to the manufacturer’s in-
structions. EBV-infected cells were observed as black-
colored signals at the hybridization site using light
microscopy. Only signals within tumor cell nuclei were
considered EBV-positive carcinomas; black signals were
seen in almost all cancer cell nuclei in EBV-positive
cases.Microsatellite instability analysis
Immunohistochemical staining for human mutL homo-
log 1 (hMLH1; Ready to use; Ventana Medical Systems)
and human mutS homolog 2 (hMSH2; Ready to use; Cell
Marque) was initially performed on full-section paraffin
blocks to screen for MSI-high cases, as reported previ-
ously [24]. Next, in cases showing loss patterns for either
hMLH1 or hMSH2 nuclear expression, we extracted the
DNA from paired normal and tumor tissues, and subse-
quently carried out MSI analysis using fluorescent multi-
plex PCR with five markers (BAT-25, BAT-26, D5S346,
D17S250, and D2S123), as recommended by the Na-
tional Cancer Institute (NCI) [25]. The PCR products
were analyzed with a DNA autosequencer (ABI 3731
Genetic Analyzer; Applied Biosystems, Foster City, CA,
USA). When a case was positive for two or moremicrosatellite markers, it was defined as MSI-high, in ac-
cordance with NCI criteria [25].
PD-L1 innate function study in gastric carcinoma cell lines
We purchased SNU601, SNU216, and SNU719 from the
Korean Cell Line Bank (Seoul, Korea), and AGS, from
the American Type Culture Collection (Manassas, VA,
USA). YCCEL1 was supplied by Dr. SY Rha [26, 27].
Cells were maintained at 37 °C in RPMI 1640 (Gibco
BRL, Rockville, MD, USA) supplemented with 10% fetal
bovine serum, 2 mmol/L L-glutamine, and antibiotics
(100 units/mL penicillin and streptomycin) in a humidi-
fied 5% CO2/95% air atmosphere.
PD-L1-specific siRNA (s26547; 5′-GGCAUUUGCU
GAACGCAUU-3′) was acquired from Ambion Applied
Biosystems (Austin, TX, USA), and a scrambled siRNA
(sc-37,007) as the negative control, from Santa Cruz Bio-
technology (Santa Cruz, CA, USA). We transfected cells
(25 × 104 in a 60 mm plate) with 200 pmol siRNA using
Lipofectamine 2000 (Invitrogen) per manufacturer’s in-
structions. After 24 h, western blot was performed; pro-
tein separated by SDS-PAGE gel was transferred onto
PVDF membranes (Millipore, Bedford, MA, USA). Each
membrane was treated with the primary antibody, PD-
L1 (17952–1-AP, 1:1000, Proteintech Fisher Scientific:
Hampton, NH, USA), and then secondary antibodies
(Cell Signaling). As a loading and transfer control, we
used an antibody against β-actin (AC-15, 1:10000,
Abcam).
To examine cellular proliferation, cells were seeded
into 96-well plates (103 cells/well) overnight, and incu-
bated with 100 μL/well of Cell Counting Kit-8 (CCK-8;
Dojindo Laboratories, Kumamoto, Japan) for 2 h in the
dark. Absorbance at 450 nm was measured using a spec-
trophotometer (Spectramax 190; Molecular Devices,
Sunnyvale, CA, USA).
As for cell invasion, 24-well BioCoat Matrigel invasion
chambers (BD Biosciences, San Diego, CA, USA) was
used. Cells (5 × 104 /well in a 24-well plate) were placed
in the upper chamber filled with 500 μL serum-free
media, and the lower chamber was filled with 700 μL
media supplemented with 10% fetal bovine serum; the
chambers were then incubated for 18 h at 37 °C. Then,
cells that invaded the lower chamber were stained with
4 μg/mL Calcein AM (BD Biosciences) in Hank’s buff-
ered saline at 37 °C for 1 h, and counted on a fluores-
cence microscope (Olympus IX71, Tokyo, Japan).
Apoptosis was calibrated with the Annexin V-FITC
apoptosis kit (BD Biosciences). Cells (10 × 104/well in a
6-well plate) were cultured in serum-free media, trypsi-
nized (Invitrogen, Carlsbad, CA, USA), centrifuged, and
re-suspended in Annexin V–binding buffer (150 mmol/L
NaCl, 18 mmol/L CaCl2, 10 nmol/L HEPES, 5 mmol/L
KCl, and 1mmol/L MgCl2). Cells were incubated with
Table 1 Relationship Between Clinicopathological Features and PD-L1 Expression and Tumor-Infiltrating Lymphocytes in the Entire
Cohort
Total (N = 514) PD-L1 in tumor cells PD-L1 in immune cells
positive negative positive negative
Sex
Male 347 (68%) 65 (19%) 282 (81%) 170 (49%) 177 (51%)
Female 167 (32%) 36 (22%) 131 (78%) 74 (44%) 93 (56%)
Age, median (years, range) 65 (27–88) 66 (27–88) 64 (29–88) 66 (27–88) 64 (30–86)
Tumor site
Lower 1/3 332 (65%) 63 (19%) 269 (81%) 156 (47%) 176 (53%)
Middle 1/3 103 (20%) 17 (17%) 86 (83%) 50 (49%) 53 (51%)
Upper 1/3 79 (15%) 21 (27%) 58 (73%) 38 (48%) 41 (52%)
Histologic type * P = 0.008 * P < 0.001
Tubular adenocarcinoma 415 (81%) 87 (21%) 328 (79%) 214 (52%) 201 (48%)
Poorly cohesive carcinoma 83 (16%) 10 (12%) 73 (88%) 22 (27%) 61 (73%)
Mucinous carcinoma 9 (2%) 0 9 (100%) 2 (22%) 7 (78%)
Undifferentiated carcinoma 7 (1%) 4 (57%) 3 (43%) 6 (86%) 1 (14%)
Lauren classification * P = 0.023 * P = 0.019
Intestinal 286 (56%) 46 (16%) 240 (84%) 149 (52%) 137 (48%)
Diffuse 228 (44%) 55 (24%) 173 (76%) 95 (42%) 133 (58%)
Lymphatic invasion * P < 0.001
Present 230 (45%) 67 (29%) 163 (71%) 100 (43%) 130 (57%)
Depth of invasion (pT) * P < 0.001 * P = 0.006
pT1 (mucosa, submucosa) 262 (51%) 29 (11%) 233 (89%) 137 (52%) 125 (48%)
pT2 (muscularis proper) 46 (9%) 10 (22%) 36 (78%) 27 (59%) 19 (41%)
pT3 (subserosa) 97 (19%) 25 (26%) 72 (74%) 42 (43%) 55 (57%)
pT4 (serosa or beyond) 109 (21%) 37 (34%) 72 (66%) 38 (35%) 71 (65%)
Lymph node metastasis * P = 0.008 * P = 0.004
Present 215 (42%) 54 (25%) 161 (75%) 86 (40%) 129 (60%)
Tumor stage (pTNM) * P < 0.001 * P = 0.008
Stage I 277 (54%) 36 (13%) 241 (87%) 148 (53%) 129 (47%)
Stage II 81 (16%) 23 (28%) 58 (72%) 39 (48%) 42 (52%)
Stage III 130 (25%) 33 (25%) 97 (75%) 49 (38%) 81 (62%)
Stage IV 26 (5%) 9 (35%) 17 (65%) 8 (31%) 18 (69%)
Total (N = 514) CD8+ population FOXP3+ population PD-1+ population
high low high low high low
Sex
Male 347 (68%) 177 (51%) 170 (49%) 161 (46%) 186 (54%) 126 (36%) 221 (64%)
Female 167 (32%) 80 (48%) 87 (52%) 79 (47%) 88 (53%) 55 (33%) 112 (67%)
Age, median (years, range) 65 (27–88) 65 (27–88) 65 (30–86) 66 (27–84) 63 (29–88) 67 (40–88) 63 (27–88)
Tumor site * P = 0.049
Lower 1/3 332 (65%) 162 (49%) 170 (51%) 162 (49%) 170 (51%) 108 (33%) 224 (67%)
Middle 1/3 103 (20%) 46 (45%) 57 (55%) 46 (45%) 57 (55%) 37 (36%) 66 (64%)
Upper 1/3 79 (15%) 49 (62%) 30 (38%) 32 (41%) 47 (59%) 36 (46%) 43 (54%)
Histologic type * P = 0.001
Tubular adenocarcinoma 415 (81%) 209 (50%) 206 (50%) 209 (50%) 206 (50%) 152 (37%) 263 (63%)
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Table 1 Relationship Between Clinicopathological Features and PD-L1 Expression and Tumor-Infiltrating Lymphocytes in the Entire
Cohort (Continued)
Poorly cohesive carcinoma 83 (16%) 37 (45%) 46 (55%) 25 (30%) 58 (70%) 22 (27%) 61 (73%)
Mucinous carcinoma 9 (2%) 4 (44%) 5 (56%) 3 (33%) 6 (67%) 1 (11%) 8 (89%)
Undifferentiated carcinoma 7 (1%) 7 (100%) 0 3 (43%) 4 (57%) 6 (86%) 1 (14%)
Lauren classification * P = 0.004 * P = 0.002
Intestinal 286 (56%) 127 (44%) 159 (56%) 151 (53%) 135 (47%) 97 (34%) 189 (66%)
Diffuse 228 (44%) 130 (57%) 98 (43%) 89 (39%) 139 (61%) 84 (37%) 144 (63%)
Lymphatic invasion * P = 0.033 * P = 0.017 * P = 0.041
Present 230 (45%) 127 (55%) 103 (45%) 94 (41%) 136 (59%) 92 (40%) 138 (60%)
Depth of invasion (pT) * P = 0.006 * P < 0.001
pT1 (mucosa, submucosa) 262 (51%) 112 (43%) 150 (57%) 152 (58%) 110 (42%) 85 (32%) 177 (68%)
pT2 (muscularis proper) 46 (9%) 31 (67%) 15 (33%) 22 (48%) 24 (52%) 20 (43%) 26 (57%)
pT3 (subserosa) 97 (19%) 54 (56%) 43 (44%) 34 (35%) 63 (65%) 34 (35%) 63 (65%)
pT4 (serosa or beyond) 109 (21%) 60 (55%) 49 (45%) 32 (29%) 77 (71%) 42 (39%) 67 (61%)
Lymph node metastasis * P < 0.001
Present 215 (42%) 112 (52%) 103 (48%) 71 (33%) 144 (67%) 77 (36%) 138 (64%)
Tumor stage (pTNM) * P < 0.001
Stage I 277 (54%) 126 (45%) 151 (55%) 163 (59%) 114 (41%) 95 (34%) 182 (66%)
Stage II 81 (16%) 50 (62%) 31 (38%) 29 (36%) 52 (64%) 30 (37%) 51 (63%)
Stage III 130 (25%) 66 (51%) 64 (49%) 39 (30%) 91 (70%) 44 (34%) 86 (66%)
Stage IV 26 (5%) 15 (58%) 11 (42%) 9 (35%) 17 (65%) 12 (46%) 14 (54%)
PD-L1 positive in tumor cells (n = 101); PD-L1 negative in tumor cells (n = 413); PD-L1 positive in immune cells (n = 244); PD-L1 negative in immune cells (n = 270)
CD8+ high (n = 257), CD8+ low (n = 257); FOXP3+ high (n = 240); FOXP3+ low (n = 274), PD-1+ high (n = 181); PD-1+ low (n = 333)
P values with statistically significant differences (< 0.05) are marked with an asterisk (*)
Choi et al. Diagnostic Pathology           (2020) 15:69 Page 5 of 15FITC-conjugated Annexin V (1 μg/mL) and propidium
iodide (50 μg/mL) for 30 min at room temperature in
the dark, and analyzed with FACScan flow cytometer
(Becton Dickinson, Mountain View, CA, USA) and Cell-
Quest software (Becton Dickinson).
Wound healing assay was performed to assess cell mi-
gration. A scratch was made in a 6-well plate of conflu-
ent cells (25 × 104/well) with the tip of a micropipette.
Images were taken 24 h later on an inverted photomicro-
scope (Olympus IX71). Movements of individual cells
were measured with NIH ImageJ software (http://rsb.
info.nih.gov/ij/index.html).
Statistical analysis
Pearson’s chi-squared test, two-tailed Student’s t-test,
Spearman’s rank correlation coefficient, and Mann-
Whitney U tests were used. Patient survival rates were
calculated using the Kaplan-Meier method and log-rank
test. We inputted parameters for which the P value <
0.05 in univariate analysis into a Cox proportional haz-
ard model (multivariate analysis) to calculate a hazard
ratio (HR) and 95% confidence interval (CI). A value of
P < 0.05 was considered statistically significant. All stat-
istical analyses were conducted in SPSS Statistics version
21.0 for Windows (IBM SPSS Inc., Armonk, NY, USA)or the R Project for Statistical Computing 3.6.3 (https://
cran.r-project.org/bin/windows/base/).
Results
Clinicopathological features, PD-L1 expression, and TILs
in the entire cohort
PD-L1(+) tumor cells were observed in 101 (20%) out of
514 cases, and PD-L1(+) immune cells were observed in
244 cases (47%) (Table 1 and Fig. 1). The dual expres-
sion of PD-L1 in both tumor and immune stromal cells
was observed in 65 cases (13%). The tumoral or immune
cell PD-L1(+) subgroup manifested many more CD8+,
FOXP3+, and PD-1+ TILs than the tumoral PD-L1(−) or
immune cell PD-L1(−) subgroup (P < 0.05, respectively)
(Supplemental Table 1 and Supplemental Fig. 1).
Prognostic value of PD-L1 expression, TILs, EBV-infection,
and MSI status in the entire cohort
The subgroup of more advanced-stage tumors (pTNM),
Lauren diffuse type, presence of lymphatic invasion, tu-
moral PD-L1(+), immune cell PD-L1(−), or FOXP3+/low
TILs was associated with lower rates of overall survival
via univariate analysis of the cohort (N = 514) (Fig. 2 and
Supplemental Table 2). Since most patients with tumor
recurrence did not survive, the above mentioned factors
Fig. 1 Immunohistochemical features of PD-L1, CD8+, FOXP3+, and PD-1+. (A-C) PD-L1 is expressed in three major patterns: a “Focal” PD-L1
expression in tumor cells and immune cells (red arrows). b “Diffuse (positive ≥10% of tumor cells)” PD-L1 expression in tumor cells and no
staining in immune cells. c PD-L1 expression in immune cells only. (D-F) Note the high population in each line of tumor-infiltrating lymphocytes
(TILs); d CD8+/high TILs, e FOXP3+/high TILs, and f PD-1+/high TILs
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vival (data not shown).
In our combined analysis of tumoral PD-L1 and each
subtype of TILs, the combined subsets of tumoral PD-
L1(+)/CD8+/low TILs, tumoral PD-L1(+)/immune cell PD-
L1(−), or tumoral PD-L1(+)/FOXP3+/low TILs showed a
worse clinical outcome based on univariate analysis
(P < 0.05, respectively). In combined analysis of three
components from tumoral PD-L1, immune cell PD-L1,
and each subtype of TILs, the combined subset of tumoral
PD-L1(+)/immune cell PD-L1(−)/CD8+/low TILs was re-
lated with an adverse clinical outcome (P < 0.05).
Multivariate analysis showed that an unfavorable progno-
sis was maintained in more advanced-stage tumors, the
subset of tumoral PD-L1(+)/CD8+/low TILs, or the subset of
tumoral PD-L1(+)/immune cell PD-L1(−)/CD8+/low TILs,
and all were independent prognostic factors (P < 0.05, each)
(Fig. 2 and Supplemental Table 2). EBV or MSI status alone
were not a prognostic factor in the cohort.
Our analysis of only patients with “advanced gastric
carcinoma” (AGC; cases with tumor invasion into the
proper muscle or deeper; N = 253) revealed that the
prognostic factors for AGC were the same as those for
the entire cohort, with two exceptions: AGC patients
with a low population of CD8+ TILs showed lower ratesof overall survival and recurrence-free survival through
univariate analysis, and the MSI-high AGC group
showed a more favorable clinical outcome (P < 0.05)
(Supplemental Fig. 2).
Clinicopathological features, PD-L1, and TILs in EBV-
positive and MSI-high gastric carcinomas
Of the 514 gastric carcinoma patients, there were 32
(6%) and 53 (10%) cases of EBV-positive and MSI-high
gastric carcinomas, respectively; No patients were both
EBV-positive and MSI-high. The remaining 429 cases of
EBV-negative/non-MSI-high cases were classified as
conventional gastric carcinomas (Fig. 3). Unlike the con-
ventional group, EBV-positive carcinomas were located
predominantly in the upper 1/3 of the stomach and were
more commonly Lauren diffuse type (P < 0.05 for each).
Additionally, MSI-high carcinomas showed more fre-
quent lymphatic invasion, deeper invasion depth, and
more advanced-stage tumors (P < 0.05) (Table 2).
EBV-positive gastric carcinomas had higher incidences of
tumoral PD-L1(+) and immune cell PD-L1(+), and larger
numbers of CD8+, FOXP3+, and PD-1+ TILs than conven-
tional gastric carcinomas (P < 0.05 for all comparisons)
(Table 3 and Supplemental Fig. 3). Specifically, tumoral
PD-L1 and immune cell PD-L1 were expressed in 15 cases
Fig. 2 Kaplan-Meier survival plots of overall survival. In the entire cohort (N = 514), the subgroups with more advanced-stage tumors (a), the
combined subset of tumoral PD-L1(+)/immune cell PD-L1(−)/CD8+low tumors (b) exhibit the lowest rates of patient survival within each
corresponding analysis based on the Cox proportional hazards model. I, II, III and IV in (A) indicate TNM tumor stage. Tumoral PD-L1(+) (c),
FOXP3+/low (d), and the combined subset of tumoral PD-L1(+)/FOXP3+/low tumors (e) reveal the lowest rates of patient survival through each
corresponding univariate analysis. Corresponding P value, hazard ratio (HR) and 95% confidence interval (CI) in the worst prognostic subset are
shown in the bottom left corner of each plot, and P values throughout all subsets, in the bottom right corner of each plot
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positive carcinomas. The CD8+/high, FOXP3+/high, and PD-
1+/high TILs were found in 30 (94% of EBV-positive sub-
group), 21 (66%), and 23 (72%) cases, respectively. All 15
tumoral PD-L1(+)/EBV-positive carcinomas were enriched
with CD8+/high TILs.
MSI-high gastric carcinomas more commonly dis-
played tumoral PD-L1(+), immune cell PD-L1(+), or
CD8+/high TILs than conventional gastric carcinomas
(P < 0.05, each) (Table 3 and Supplemental Fig. 3). Spe-
cifically, tumoral PD-L1(+), immune cell PD-L1(+), and
CD8+/high TILs were observed in 27 (51% of MSI-high
carcinomas), 28 (53%), and 38 cases (72%), respectively.
Prognostic value of PD-L1 and TILs in EBV-positive gastric
carcinomas and MSI-high gastric carcinomas
In EBV-positive gastric carcinomas, the tumoral PD-L1(+)
subgroup showed lower rates of overall survival (P < 0.05)
(Fig. 4 and Supplemental Table 3), and recurrence-free
survival (data not shown). Through further univariate ana-
lysis of tumoral PD-L1 status combined with each line of
TILs, tumoral PD-L1(+)/FOXP3+/low TILs revealed a
worse clinical outcome (Fig. 4 and Supplemental Table 4);however, tumor stage (pTNM) was the only independent
prognostic factor in EBV-positive gastric carcinomas. The
prognostic significance of tumoral PD-L1(+)/CD8+/low
TILs could not be statistically evaluated in the EBV-
positive group because all tumoral PD-L1(+)/EBV-positive
cases contained CD8+/high TILs (Supplemental Fig. 4).
In MSI-high gastric carcinomas, the combined subset of
tumoral PD-L1(+)/CD8+/low TILs or tumoral PD-L1(+)/im-
mune cell PD-L1(−)/CD8+/low TILs was associated with an
adverse outcome for patients (P < 0.05, each) (Fig. 4). None
of other parameters showed a prognostic impact on overall
survival or recurrence-free survival through univariate ana-
lysis. Accordingly, multivariate analysis could not be per-
formed reliably. The covariate parameters of multivariate
analysis must include significant factors from univariate
analysis, and factors containing the same parameter (tu-
moral PD-L1 in this situation) should not be considered to-
gether when doing multivariate analysis.
Effects of PD-L1 knockdown in gastric carcinoma cells lines
Cell proliferation, invasion and migration were lower in
PD-L1-specific siRNA transfected cells than in scram-
bled siRNA-transfected control cells, whereas apoptosis
Fig. 3 Representative features of each molecular group. a, c, e Hematoxylin and eosin-stained images of each group. a-b Epstein-Barr virus (EBV)-
positive gastric carcinoma; b Black signals are detected in most tumor cell nuclei by in situ hybridization for EBV-encoded small RNAs. c-d
Microsatellite instability (MSI)-high gastric carcinoma; d Microsatellites are recognized for five markers (BAT26, BAT25, D5S346, D17S250, and
D2S123) by multiplex PCR, and are indicated with asterisks (*). e-g Conventional carcinoma (EBV-negative and non-MSI-high); hMLH1 f and
hMSH2 g were retained in tumor cell nuclei
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tric carcinoma cell lines; they were all statistically signifi-
cant in two EBV-positive cell lines (Fig. 5), but not all in
EBV-negative cell lines (Fig. 6). Specifically, SNU601
cells (EBV-negative) showed statistically significant dif-
ferences with regard to proliferation, invasion, migration,
and apoptosis, similar to the two EBV-positive cell lines.
Our data imply that innate role of PD-L1 may be a facili-
tator of cancer cell survival.
Discussion
The present study indicates that the prognostic value of
PD-L1 is complex, and contingent on the tumor micro-
environment, and EBV and MSI statuses. There has been
few study analyzing combined three components of “tu-
moral PD-L1, immune cell PD-L1 and TILs” in a single
study all together. In this study, the combined subset of
“tumoral PD-L1(+)/immune cell PD-L1(-)/CD8+/low
TILs” predicted a worse clinical outcome and were an
independent prognostic factor; however, individual PD-L1 or CD8+ TILs alone did not have an independent
prognostic significance. In addition, CD8+/low TILs was a
worse prognostic factor in AGC group (Supplemental
Fig. 2), specifically in tumor stage III (Supplemental
Fig. 5) as assessed through univariate analysis. Unexpect-
edly, CD8+/low TILs was correlated with well-known fa-
vorable prognostic factors such as Lauren intestinal type,
less lymphatic invasion, and earlier tumor stage (Supple-
mental Table 5). In addition, tumoral PD-L1(+)/FOX-
P3+/low TILs were associated with an unfavorable clinical
outcome in the entire cohort, EBV-positive subgroup,
and MSI-high subgroup through univariate analysis,
while tumoral PD-L1(+)/immune cell PD-L1(−) status
was associated with an unfavorable clinical outcome in
the entire cohort only. Our combined analysis, which
accounted for TILs in the tumor microenvironment,
may provide reliable results regarding the prognostic
value of PD-L1 expression. In this study, tumoral PD-L1
expression alone was an adverse prognostic factor,
through univariate analysis, for all patients except those
Table 2 Clinicopathological Features in Each Molecular Group
Conventional EBV-positive MSI-high
(n = 429) (n = 32) (n = 53)
Sex
Male 290 (68%) 24 (75%) 33 (62%)
Female 139 (32%) 8 (25%) 20 (38%)
Age, median (years, range) 65 (27–88) 63 (45–88) 64 (34–82)
Tumor site *a P < 0.001
Lower 1/3 287 (67%) 4 (13%) 41 (77%)
Middle 1/3 85 (20%) 11 (34%) 7 (13%)
Upper 1/3 57 (13%) 17 (53%) 5 (9%)
Histologic type *b P = 0.006
Tubular adenocarcinoma 343 (80%) 29 (91%) 43 (81%)
Poorly cohesive 76 (18%) 2 (6%) 5 (9%)
Mucinous carcinoma 5 (1%) 0 4 (8%)
Undifferentiated 5 (1%) 1 (3%) 1 (2%)
Lauren *a P = 0.029
Intestinal 246 (57%) 12 (38%) 28 (53%)
Diffuse 183 (43%) 20 (63%) 25 (47%)
Lymphatic invasion *b P < 0.001
Present 182 (42%) 11 (34%) 37 (70%)
Depth of invasion (pT) *b P = 0.031
pT1 (mucosa, submucosa) 229 (53%) 17 (53%) 16 (30%)
pT2 (muscularis proper) 37 (9%) 3 (9%) 6 (11%)
pT3 (subserosa) 79 (18%) 2 (6%) 16 (30%)
pT4 (serosa or beyond) 84 (20%) 10 (31%) 15 (28%)
Lymph node metastasis
Present 177 (41%) 10 (31%) 28 (53%)
Tumor stage (pTNM) *b P = 0.028
Stage I 238 (55%) 20 (63%) 19 (36%)
Stage II 64 (15%) 3 (9%) 14 (26%)
Stage III 105 (24%) 7 (22%) 18 (34%)
Stage IV 22 (5%) 2 (6%) 2 (4%)
EBV Epstein-Barr virus, MSI Microsatellite instability; Conventional, EBV-negative
and non-MSI-high
P values with statistically significant differences (< 0.05) are marked with an
asterisk (*)
aP value between EBV-positive gastric carcinomas and conventional
gastric carcinomas
bP value between MSI-high gastric carcinomas and conventional
gastric carcinomas
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on cell proliferation, invasion, migration and apoptosis
using PD-L1 knockdown in gastric carcinoma cell lines
demonstrated that the innate function of PD-L1 was to
foster cancer cell survival, which is in line with prior
studies [28, 29]. The exact mechanisms by which PD-L1
exerts innately oncogenic effects remain to be better de-
fined. The underlying processes may be related to be
that PD-L1 expression is intrinsically regulated viavarious oncogenic pathways as well as extrinsically medi-
ated via cytokines in tumor microenvironment [30]. As a
fundamental immunology concept, tumoral PD-L1 ex-
pression helps the tumor to evade host immune surveil-
lance, possibly contributing to more severe outcomes in
cancer patients. However, the prognostic impact of tu-
moral PD-L1 expression in gastric carcinomas has been
contradictory; poor [12–15], good [16], and neutral [17]
prognostic outcomes have all been reported. The reasons
for these discordant results largely lie in the use of dif-
ferent antibodies and cut-off values in the evaluation of
PD-L1 expression [31]. Further, we addressed additional
possibilities for the reasons, namely the analysis of indi-
vidual factors only, the analysis of a small series, or po-
tential selection bias (non-consecutive cases). The
present study is important because it included a com-
bined analysis of PD-L1, multiple lines of TILs, and
EBV-infection and MSI status together in the same co-
hort of a large series composed of consecutive
surgically-resected gastric carcinomas.
The present report advocates that immune cell PD-L1
expression may predict a better clinical outcome. Over-
all, PD-L1(+) in immune cells were a favorable prognos-
tic indicator. This may be because immune cell PD-L1 is
regulated via an adaptive mechanism within the context
of persistent tumor antigen-specific immune stimulation
and reflects a pre-existing robust antitumor immunity,
which may contribute to tumor surveillance and cyto-
toxic antitumor activity [32]. Similar to our results, pre-
vious studies have shown that PD-L1(+) in immune cells
are associated with a favorable prognosis in gastric car-
cinomas [33–35]. In mouse models, PD-L1-expressing
cytotoxic T cells seem to participate in antitumor im-
mune responses via enhanced survival and potent expan-
sion of cytotoxic T cells [36]. In contrast, PD-L1 in
stromal immune cells has been shown to be involved in
mediating the immune suppression of antitumor T cell
responses [37]. Further studies are warranted to explain
these contradictory data.
The present report suggests that FOXP3+ TILs may lean
towards a good prognostic outcome. A possible explanation
for our results is that FOXP3+ cells can suppress tumor-
promoting proinflammatory cytokines that lead to malig-
nancy [38]. This hypothesis is supported by our observation
that a high population of FOXP3+ cells was prevalent in
early-stage tumors, as reported in previous studies [39].
Currently, the prognostic role of FOXP3+ TILs in gastric
carcinomas remains unanswered; a high population of
FOXP3+ TILs has been associated with both a better [22,
40] and worse prognosis [41], or not a reliable marker [6].
There is an argument that FOXP3+ TILs may have hetero-
geneous properties that are affected by the tumor site, and
possibly the molecular subtype, mirroring different contexts
within different tumor microenvironments [42, 43].
Table 3 Comparison of PD-L1 Expression and Tumor-Infiltrating Lymphocytes in Each Molecular Group
Conventional (n = 429) EBV-positive (n = 32) MSI-high (n = 53)
PD-L1 in tumor cells *a P < 0.001 *b P < 0.001
Positive 59 (14%) 15 (47%) 27 (51%)
Negative 370 (86%) 17 (53%) 26 (49%)
PD-L1 in immune cells *a P < 0.001
Positive 186 (43%) 30 (94%) 28 (53%)
Absent 243 (57%) 2 (6%) 25 (47%)
CD8+ *a P < 0.001 *b P < 0.001
High 189 (44%) 30 (94%) 38 (72%)
Low 240 (56%) 2 (6%) 15 (28%)
FOXP3+ *a P = 0.036
High 199 (46%) 21 (66%) 20 (38%)
Low 230 (54%) 11 (34%) 33 (62%)
PD-1+ *a P < 0.001
High 142 (33%) 23 (72%) 16 (30%)
Low 287 (67%) 9 (28%) 37 (70%)
EBV Epstein-Barr virus, MSI Microsatellite instability; Conventional, EBV-negative and non-MSI-high
P values with statistically significant differences (< 0.05) are marked with an asterisk (*)
aP value between EBV-positive gastric carcinomas and conventional gastric carcinomas
bP value between MSI-high gastric carcinomas and conventional gastric carcinomas
Fig. 4 Kaplan-Meier plots of overall survival in EBV-positive or MSI-high gastric carcinomas. a-c In EBV-positive gastric carcinomas (N = 32), more
advanced-stage tumors (a), tumoral PD-L1(+) (b), and the combined subset of tumoral PD-L1(+)/FOXP3+/low TILs (c) are associated with lower
rates of patient survival. I, II, III and IV in (a) indicate TNM tumor stage. d-e In MSI-high gastric carcinomas (N = 53), the combined subsets of
tumoral PD-L1(+)/CD8+/low TILs (d) and tumoral PD-L1(+)/immune cell PD-L1(−)/CD8+/low TILs (e) show a worse overall survival rate.
Corresponding P value, hazard ratio (HR) and 95% confidence interval (CI) in the worst prognostic subset are shown in the bottom left corner of
each plot, and P values throughout all subsets, in the bottom right corner of each plot
Choi et al. Diagnostic Pathology           (2020) 15:69 Page 10 of 15
Fig. 5 Effect of PD-L1 knockdown on cell biologic properties in EBV-positive gastric carcinoma cell lines. In YCCEL1 (left column) and SNU719
cells (right column), cell proliferation (a), invasion (b) and migration (c) are lower in PD-L1-specific siRNA transfected cells than scrambled siRNA-
transfected cells, and apoptosis (e) is higher (P < 0.05). d There was a limitation on a wound-healing assay for migration in SNU719 cells; they
grew in an aggregate pattern and thus, were not scratched with a pipette. X-axis denotes
Choi et al. Diagnostic Pathology           (2020) 15:69 Page 11 of 15In the present study, we propose that the extrinsic
mechanism in tumoral PD-L1 expression may act more
often in EBV-positive and MSI-high gastric carcinomas,indicating that PD-1/PD-L1 blockade immunotherapy
may be advantageous in these patients. In our study, tu-
moral PD-L1(+)/ CD8+/high TILs were more prevalent in
Fig. 6 Effect of PD-L1 knockdown on cell biologic properties in EBV-negative gastric carcinoma cell lines. SNU 601 cells (in left column) show
lower cell proliferation (a), invasion (b) and migration (c), and higher apoptosis (d) in PD-L1-specific siRNA cells than scrambled siRNA-transfected
mock cells (P < 0.05). However, in SNU216 cells (in middle column) and AGS cells (in right column), PD-L1-specific siRNA cells reveal statistically
significant decreases in invasion and migration compared to scrambled siRNA-transfected mock cells (P < 0.05), but not statistically significant
changes in proliferation and apoptosis
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ventional group. This suggests that PD-L1 expression in
tumor cells develops via an extrinsic mechanism (i.e.,
adaptive immune resistance), in which tumoral PD-L1expression is extrinsically derived in response to the ex-
pression of inflammatory cytokines (in particular, to
interferon-γ that is released by CD8+ cytotoxic T cells)
[44]. Furthermore, we found that diffuse expression of
Choi et al. Diagnostic Pathology           (2020) 15:69 Page 13 of 15PD-L1 in a strong intensity was more frequently ob-
served in the EBV-positive subgroup than in the conven-
tional subgroup (13% versus 5% of tumoral PD-L1
expressing-cases, respectively). Thus, extrinsic and in-
trinsic mechanisms in tumoral PD-L1 expression may
work together more commonly in EBV-positive gastric
carcinomas. The amplification of chromosomal region
9p24.1, which includes the PD-L1 gene, to promote in-
trinsic expression of PD-L1 has been reported in 15% of
EBV-positive gastric carcinomas [45]. Our results in the
EBV-positive and MSI-high groups are consistent with
those of previous reports: namely, the proportion of
EBV-positive and MSI-high cases within the entire co-
hort, the more frequent tumoral PD-L1(+) and abundant
CD8+ TILs in both subgroups, tumoral PD-L1(+) as an
unfavorable prognostic indicator in the EBV-positive
subgroup, and the mutually exclusive nature of EBV-
positive and MSI-high status [12, 46, 47].
Our study has inherent limitations. First, our retro-
spective study merely represents immune context at the
time of surgical resection, but not time-dependent dy-
namic immune heterogeneity. Second, we used only
MLH1/MSH2 immunohistochemistry to screen cases for
MSI multiplex PCR. We might miss out MSI cases with
the isolated loss of PMS2 or MSH6, although those may
be exceptional, at the least, in gastric carcinomas. Re-
cently, Mathiak et al. reported that none of MSI-high
gastric carcinomas has shown the isolated loss of MSH6
or PMS2 [48], which are more likely to be associated
with Lynch syndrome due to a germline mutation in one
of these genes [49]. Lastly, considering expression het-
erogeneity within the tumor, immunohistochemistry in
as large a portion of tissue as possible, such as multiple
full-sectioned tissues, would be better, but this is almost
impractical. Instead, we utilized tissue microarray blocks
composed of two tissue cores for each case in the dee-
pest tumor invasion portion.Conclusions
The prognostic impact of PD-L1 is determined by the
tumor microenvironment, and statuses of EBV and MSI.
Tumoral or immune cell PD-L1 on their own are not in-
dependent prognostic factors, but they have a prognostic
significance in certain molecular groups. Notably, the
combination of PD-L1 expression and CD8+ TILs may
serve as an independent prognostic factor. The com-
bined subset of “tumoral PD-L1(+)/immune cell PD-L1(-
)/CD8+/low TILs” shows a worse prognosis. This may be
advantageous for combinatorial therapies of PD-L1/PD-
1 and cytotoxic T-lymphocyte associated antigen 4
blockades that would bring the activation and prolifera-
tion of effector T cells, thereby restoring the immune
system toward attacking the tumor [50].Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13000-020-00979-z.
Additional file 1: Supplemental Figure 1. Correlation between PD-L1
expression and multiple lines of tumor-infiltrating lymphocytes (TILs). The
tumoral PD-L1(+) subgroup (A-C) or immune cell PD-L1(+) subgroup (D-
F) displays many more CD8+, FOXP3+, and PD-1+ TILs than each respect-
ive PD-L1(−) subgroup.
Additional file 2: Supplemental Figure 2. Kaplan-Meier plots of over-
all survival in advanced gastric carcinomas (AGC) (n = 253). Among ad-
vanced gastric carcinomas, subgroup containing tumors with CD8+/high
(A), and MSI-high subgroup (B) show more favorable outcomes than
CD8+/low or conventional subgroup, respectively. Corresponding P value,
hazard ratio (HR) and 95% confidence interval (CI) in the worst prognostic
subset are shown in the bottom left corner of each plot, and P values
throughout all subsets, in the bottom right corner of each plot.
Additional file 3: Supplemental Figure 3. Comparison of the
quantities of CD8+, FOXP3+, and PD-1+ TILs in the different molecular
groups. CD8+ (A), FOXP3+ (B), and PD-1+ (C) TILs are more highly abun-
dant in EBV-positive (EBV+) carcinomas than in conventional carcinomas.
In MSI-high (MSI-H) carcinomas, only CD8+ TILs are significantly enriched
compared to conventional carcinomas. * P < 0.05, ** P < 0.01, *** P <
0.001.
Additional file 4: Supplemental Figure 4. Distribution of tumoral PD-
L1 combined with CD8+ population in each molecular subgroup. The
EBV-positive and MSI-high (MSI-H) subgroups show a higher frequency of
tumoral PD-L1(+)/CD8+/high TILs than the conventional subgroup (P <
0.05, each).
Additional file 5: Supplemental Figure 5. Kaplan-Meir plots of overall
survival in each tumor stage according to the density of CD8+ TILs. Corre-
sponding P value, hazard ratio (HR) and 95% confidence interval (CI) in
the worst prognostic subset are shown in the bottom left corner of each
plot, and P values throughout all subsets, in the bottom right corner of
each plot.
Additional file 6: Supplemental Table 1. Correlation Between PD-L1
Expression and Tumor-Infiltrating Lymphocytes (TILs) in the Entire Cohort
(N = 514)
Additional file 7: Supplemental Table 2. Univariate and Multivariate
Analyses in the Entire Cohort (N = 514) (corresponding to Fig. 2a, b & e)
Additional file 8: Supplemental Table 3. Univariate and Multivariate
Analyses in EBV-positive Gastric Carcinomas (n = 32) (corresponding to
Fig. 4a & c)
Additional file 9: Supplemental Table 4. Univariate Analysis in MSI-
high Gastric Carcinomas (n = 53) (corresponding to Fig. 4d & e)
Additional file 10: Supplemental Table 5. Comparison of
Clinicopathologic Characteristics, and Statuses of PD-L1, FOXP3+, and PD-
1+ According to the Density of CD8+ TILs in the Entire Cohort (N = 514)
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